EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia

Aubrey Martin, Neda Shokrian, Kristen J Kelley, Joel Correa da Rosa, Ester Del-Duca, Robert Bissonnette, Ole E Sørensen, Anders Bacher Nielsen, Emma Guttman-Yassky, Maryanne Makredes Senna

Journal of Investigative Dermatology · 2026-05 · 146 (5) · 1265-1270.e7

DOI: 10.1016/j.jid.2025.09.375 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Investigative Dermatology, 2026-05. Verfasst von Aubrey Martin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA. Hauptthemen laut MEDLINE: Alopecia, Janus Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, LEO Pharma A/S, Scarring Alopecia Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Frontal fibrosing alopecia (FFA) is a cicatricial alopecia with generally poor prognosis if untreated and no approved treatment options. OBJECTIVE: The aim of this study was to evaluate changes in the molecular signature of FFA lesions after application of delgocitinib cream. Safety, tolerability, and efficacy were also investigated. METHODS: This was a phase 2a, randomized, double-blind, exploratory trial of 20 mg/g delgocitinib cream (2%) versus cream vehicle in patients with FFA. RESULTS: A total of 30 adult females with FFA were randomized to delgocitinib cream (n = 15) or cream vehicle (n = 15). After 12 weeks, expression of the T helper 1-related biomarker CXCL9 was significantly downregulated (-3.10; P < .05), whereas there were nonsignificant reductions in CXCL10 (-2.60; P < .1) and IFN-γ (-1.49; P = .22) in lesions treated with delgocitinib cream but not cream vehicle. Delgocitinib-treated lesions had a small but significant mean improvement in transcriptomic profile (4%; P < .001), whereas lesions treated with cream vehicle worsened (33%). Delgocitinib cream was well-tolerated and associated with improvements in exploratory clinical severity endpoints. LIMITATIONS: Limitations of the trial include small sample size, biomarker analyses only being conducted to week 12, and the exploratory nature of efficacy endpoints. CONCLUSION: Delgocitinib cream resulted in an improvement in the transcriptomic profile of lesions and may have potential as a topical treatment for FFA. This study is registered with NCT05332366.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlopeciaJanus Kinase InhibitorsHumansFemaleAdultDouble-Blind MethodMiddle AgedTreatment OutcomeChemokine CXCL9FibrosisSkin CreamChemokine CXCL10Administration, TopicalPyrroles

Stichwörter der Autor:innen

FibrosisIFN-γPhase 2a trialScarring alopecia

Substanzen

Janus Kinase InhibitorsdelgocitinibChemokine CXCL9CXCL9 protein, humanCXCL10 protein, humanChemokine CXCL10Pyrroles

Autor:innen und Institutionen

  • Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Innovaderm Research, Montreal, Canada.
  • LEO Pharma A/S, Ballerup, Denmark.
  • Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA; Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: msenna@lahey.org.

Förderung

  • Pfizer
  • LEO Pharma A/S
  • Scarring Alopecia Foundation
  • Eli Lilly and Company

Zitieren

APA

Martin, A., Shokrian, N., Kelley, K. J., Correa da Rosa, J., Del-Duca, E., Bissonnette, R., Sørensen, O. E., Nielsen, A. B., Guttman-Yassky, E., & Senna, M. M. (2026). Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia. Journal of Investigative Dermatology, 146(5), 1265-1270.e7. https://doi.org/10.1016/j.jid.2025.09.375

Vancouver

Martin A, Shokrian N, Kelley KJ, Correa da Rosa J, Del-Duca E, Bissonnette R, et al. Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia. Journal of Investigative Dermatology. 2026;146(5):1265-1270.e7. doi:10.1016/j.jid.2025.09.375

BibTeX
@article{Martin2026,
  author = {Martin, Aubrey and Shokrian, Neda and Kelley, Kristen J and Correa da Rosa, Joel and Del-Duca, Ester and Bissonnette, Robert and Sørensen, Ole E and Nielsen, Anders Bacher and Guttman-Yassky, Emma and Senna, Maryanne Makredes},
  title = {Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia},
  journal = {Journal of Investigative Dermatology},
  year = {2026},
  volume = {146},
  number = {5},
  pages = {1265--1270.e7},
  doi = {10.1016/j.jid.2025.09.375}
}
Kostenlos starten →